Antibacterial Drug R&D – Medical Need and Public Support
Delivered by U. Theuretzbacher – Center for Anti-Infective Agents, Vienna, Austria
2017 BioInfect Conference held on 02 November 2017, Alderley Park Conference Centre, Cheshire
Quality indicators and quantitative metrics for responsible antibiotic use, lessons from DRIVE-AB project
Delivered by Vera Vlahovic-Palcevski, DRIVE-AB
British Society for Antimicrobial Chemotherapy Spring Conference, 14 March 2017, London.
Driving innovation by delinking investment in antibiotic R&D from sales revenues
Delivered by Kevin Outterson, Boston University School of Law and Chatham House
Re-entering Antibacterial Discovery and Development Summit, held on 9 December, 2016, Boston.
Ecology and environmental drivers of antibiotic resistance
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
International Meeting on Emerging Diseases and Surveillance, held on 4-7 November 2016, Vienna.
Strengthening AMR R&D by coordination, cooperation and knowledge exchange
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
World Health Summit side event, “Global expert network conference on innovations in antimicrobial drug research and development”, Berlin, October 2016
Inadequate antibiotic pipelines and international initiatives to stimulate innovation and sustainable use of antibiotics
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID) 33rd Annual Meeting, Finland, September 2016
Economic incentives for antibiotics: The DRIVE-AB approach
Delivered by Kevin Outterson, Boston University School of Law and Chatham House
Presidential Advisory Council on Combating Antibiotic Resistant Bacteria meeting (PACCARB) meeting, June 2016
How to stimulate and incentivize the development of needed, new antibiotics
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
Bio2Device Group, Palo Alto, USA, June 2016
Review of the health technology assessment (HTA) process for antibiotics in Europe
Delivered by Abigail Colson, University of Strathclyde
16th Biennial European Conference, London, June 2016
New economic models for antibiotic R&D
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
Gulf Congress of Clinical Microbiology and Infectious Disease, Dubai, May 2016
Worldwide initiatives to control AMR and role of antimicrobial stewardship
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
Antibiotics-Now!, University of Groningen, May 2016
The antibiotic pipeline: What can we expect?
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
17th International Congress on Infectious Diseases (ICID), Hyderabad, India, 2016
Incentivizing Antibiotic Innovation
Delivered by Christine Årdal, Norwegian Institute of Public Health
17th International Congress on Infectious Diseases (ICID), Hyderabad, India, 2016
Review of possible funding/incentive mechanisms and opportunities
Delivered by John-Arne Røttingen, Norwegian Institute of Public Health
WHO & DNDi Technical Consultation: Investing in the development of new antibiotics and their conservation, Geneva, 2015
DRIVE-AB: Driving Re-Investment in R&D and Responsible Antibiotic Use
Delivered by John-Arne Røttingen, Norwegian Institute of Public Health
First HTA stakeholder meeting, Oslo, 2015
Economics of Antibiotic Resistance
Delivered by Ramanan Laxminarayan, Center for Disease Dynamics, Economics and Policy (CDDEP)
Latsis Symposium, Zürich, 2015
Creating, Testing and Validating New Economic Models for Antibiotic R&D
Delivered by Christine Årdal, Norwegian Institute of Public Health
Stimulating the antimicrobial pipeline: A global perspective, Washington DC, 2015
Why should we care about multi-resistant bacteria? Clinical impact and public health implications
Delivered by Prof Stephan Harbarth, Université de Genève / Infection Control Program
Geneva Pharma Forum, Geneva, 2015
Enabling drug discovery and development to address the crisis of antibacterial resistance: New tools, new pathways and remaining challenges
Delivered by Dr John Rex, AstraZeneca
Geneva Pharma Forum, Geneva, 2015
DRIVE-AB and the role of SMEs in antibacterial drug R&D
Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
DRIVE-AB Stakeholder Meeting, 2015, London, 2015
Development of National Antimicrobial Stewardship and Prescribing Competences
Delivered by Diane Ashiru-Oredope, Public Health England
BSAC Spring Meeting, London, 2014